secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001493152-24-034737
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack appoints CEO Paul Goode and biotech veteran John Ballantyne to Board of Directors
--------------------------------------------------------------------------------

- CEO Paul V. Goode appointed as a board member, effective August 27, 2024.
- John Ballantyne, former Aldevron co-founder and CSO, appointed to board effective immediately.
- Ballantyne brings 20+ years biotech experience; served as CSO through Danaher acquisition.
- Ballantyne's background expected to aid commercialization of Glucotrack's implantable CGM technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315224034737/0001493152-24-034737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315224034737/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-034737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer